Hong Kong Innovation

Hong Kong Innovation is a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics for oncology. The company primarily targets the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) pathways to treat various solid tumors, including non-small cell lung cancer and breast cancer. Their lead programs involve irreversible tyrosine kinase inhibitors designed to overcome resistance mechanisms found in traditional therapies. Hong Kong Innovation operates with a focus on the Greater China market while maintaining global development standards for its pipeline. The company leverages its expertise in medicinal chemistry to optimize drug candidates for improved efficacy and safety profiles.